# TraumaShield > TraumaShield is developing the world's first real-time drug-device intervention for post-trauma disorder prevention: an FDA-approved compound, delivered by a dedicated, innovative field device in the golden hours immediately after a traumatic event, to prevent post-traumatic stress disorder (PTSD) before it forms. Operating in stealth and Phase II ready. ## In one line - What: a real-time drug-device intervention that prevents PTSD, rather than treating it for the rest of a person's life. - How: a single, non-invasive dose of an FDA-approved compound with a known safety profile, given a new medical use, delivered by a dedicated single-use field device. - When: immediately after a traumatic event, inside the golden hours (0–6 hours), while fear memories are still being consolidated. ## Why it matters - 70% of people will experience trauma in their lifetime; 13 million Americans live with PTSD. - There is no FDA-approved way to prevent PTSD. Every existing treatment waits for the damage, then manages symptoms for years. - Caring for one PTSD patient costs about $19,630 a year. TraumaShield is a $300 one-time intervention: 65× the cost avoided per patient-year. ## Science and evidence - Acts on the brain's fear-memory circuits during the consolidation window, so the event is stored as a past memory rather than an ongoing threat. - Independent, peer-reviewed human data show a statistically significant reduction of about 45% in PTSD incidence (p < 0.05), reproduced in preclinical models. ## Why TraumaShield is a compelling opportunity - First mover in PTSD prevention, a category with no approved product. - De-risked development: building on an FDA-approved compound, the FDA 505(b)(2) drug-device pathway moves straight to Phase II. - Phase II ready: protocol complete, principal investigator and pilot centers secured, FDA pre-IND package prepared. - Protected: patent filed on the second medical use and the combination device. - Institutional buyers who bear the cost of PTSD: EMS and trauma centers, defense and military, and urgent psychiatric clinics. - Strong unit economics: a single-use consumable with scheduled kit replacement and a gross margin above 80%. - $2.85B U.S. serviceable market. - Platform pipeline: TS-01 (PTSD prevention, Phase II ready), TS-02 (PTSD treatment, planned), TS-Anx/Dep-01 (prevention of depression and anxiety after trauma, concept). - Validated by: an Israel Innovation Authority grant, selection for the Mamram Lift 2 and D.Tech by SouthUp accelerators, and a partnership with Mindful Care, the largest psychiatric urgent-care network in the United States. ## An extraordinary team - David Slobodiansky, Co-founder & CEO: neuroscientist and business executive (M.Sc. and B.Sc. in Neuroscience, both magna cum laude, Bar-Ilan University); founded TraumaShield and led it to Phase II readiness; previously directed the nationwide Sales & Marketing Division of Panorama Hatzafon, managing more than $30 million in annual sales. - Prof. Joseph Zohar, Medical Officer: one of the world's leading authorities on PTSD, whose research established the scientific basis for secondary prevention; former Director of Psychiatry at Sheba Medical Center; Past President of the European College of Neuropsychopharmacology; 400+ papers. - Dr. Amnon Gavish, Co-founder & COO: healthcare and technology executive with 30+ years building and commercializing companies; former CEO of TytoCare North America and global Chief Commercial Officer; senior roles at Amwell, Vidyo and RADVISION. - Dr. Daniel Kolsky, Co-founder & Clinical Lead: physician and neuroscientist (M.D. summa cum laude, Tel Aviv University; M.Sc., University of Oxford). - Prof. Eyal Fruchter, Clinical Operations: former Head of Mental Health of the Israel Defense Forces Medical Corps and former Head of Psychiatry at Rambam Health Care Campus. - Dr. Sharon Daniel, Biostatistics & Innovation: Head of Innovation and Research at Clalit Health Services, Southern District. - Dr. Shai Yarkoni, Business & Strategy Advisor: physician-scientist and biopharma executive who has led multiple Nasdaq-listed biopharmaceutical companies, including Cellect Biotechnology. - Ariel Ness, Business & Strategy Advisor: technology executive, investor and investor-relations advisor; Founder and Managing Director of Vega Ventures. - Advisors also include a former FDA psychiatry reviewer, a Past President of the International Society for Traumatic Stress Studies (Emory University), former biopharma chief medical officers, and a biotech CEO who led a company to a Nasdaq listing. ## Vision Trauma is inevitable. PTSD is preventable. TraumaShield is building a world where trauma becomes a memory, not a lifelong disorder, and where post-trauma disorders, including PTSD, depression and anxiety, are prevented at their core. ## Investors and partners TraumaShield engages selectively with investors and strategic partners aligned with its clinical and defense mission. Executive summary, investor deck and full data are shared under NDA. Investor briefings and clinical, defense and EMS partnerships: david@traumashield.co ## Pages - Home: https://traumashield.co/ - Science & Technology: https://traumashield.co/science - Team: https://traumashield.co/team - Investment: https://traumashield.co/investment - Contact: https://traumashield.co/contact - Privacy Policy: https://traumashield.co/privacy - Terms of Use: https://traumashield.co/terms TraumaShield's product candidate is investigational and has not been approved by the FDA or any other regulatory authority. This summary contains forward-looking statements and is not an offer of securities.